External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology EAU 2025
Roche and Genentech at

EAU 2025

March 21 - March 24
Madrid, Spain
eaucongress.uroweb.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Mar 21 / Roche and Genentech
A randomised, double-blind phase II study of autogene cevumeran + nivolumab (nivo) vs. nivo as adjuvant therapy for patients with high-risk muscle-invasive urothelial carcinoma (MIUC)
The main purpose of the study is to evaluate the efficacy of adjuvant treatment with autogene cevumeran (mRNA-based cancer vaccine) plus nivolumab compared with nivolumab in participants with high risk muscle-invasive urothelial cancer (MIUC).
Oncology Urothelial Cell Carcinoma EAU-2025
03:10 PM
Duration 20mins Madrid, Spain
A randomised, double-blind phase II study of autogene cevumeran + nivolumab (nivo) vs. nivo as adjuvant therapy for patients with high-risk muscle-invasive urothelial carcinoma (MIUC)
James Catto, David Aggen, Petros Grivas, Yohann Loriot, Javier Puente Vazquez, Srikala Sridhar, Irina Ianculescu, Jacqueline Vuky, Viraj Degaonkar, Lucia Xiaoyan Liu, Mahesh Yadav, Juergen Gschwend, Thomas Powles
Oncology | Urothelial Cell Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.